Keyword: Michael J. Fox Foundation
Parkinson's patients in a trial of Novartis' Tasigna showed a boost in dopamine that may have halted the decline of motor and non-motor functions.
The Michael J. Fox Foundation and 23andMe are launching a network aimed at combining the patient voice and genetic data from Parkinson’s patients.
The funding will support research intended to improve the chances that Inflazome will succeed in the clinic.
Charles River Laboratories and The Michael J. Fox Foundation for Parkinson’s Research have extended their collaboration.
The new “Parkinson’s Clinical Trial Companion” education suite has two parts: one for potential participants and the other for researchers.
Juno tapped Genentech alum Sunil Agarwal as new R&D chief, Merrimack promoted Onivyde scientist Daryl Drummond as head of research, and Mitch Gold leads the newly merged Alpine.
Mission Therapeutics and the University of Oxford have landed a Michael J. Fox Foundation grant to fund testing of USP30 inhibitors.
Intec Pharma has again tapped the Michael J. Fox Foundation for Parkinson’s Research for development of its Parkinson’s med AP-CD/LD.
The Michael J. Fox Foundation has expanded its trial platform to include patients with atypical parkinsonism, an umbrella term for various rare diseases.
A blood cancer drug called Tasigna (nilotinib) marketed by Swiss Big Pharma Novartis will be tested in Parkinson’s patients in the hope that it may produce disease-modifying effects.